These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31011436)

  • 1. Prognostic value of B7-H1, B7-H3 and the stage, size, grade and necrosis (SSIGN) score in metastatic clear cell renal cell carcinoma.
    Mischinger J; Fröhlich E; Mannweiler S; Meindl C; Absenger-Novak M; Hutterer GC; Seles M; Augustin H; Chromecki TF; Jesche-Chromecki J; Pummer K; Zigeuner R
    Cent European J Urol; 2019; 72(1):23-31. PubMed ID: 31011436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BioScore (B7-H1, survivin, and Ki-67) does not predict cancer-specific mortality in surgically treated patients with renal cell carcinoma: An external validation study.
    Hutterer GC; Posch F; Buser L; Zigeuner R; Morshäuser L; Otto W; Wild PJ; Burger M; May M; Pichler M; Brookman-May SD
    Urol Oncol; 2019 Jul; 37(7):510-518. PubMed ID: 31060796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Establishment and validation of a novel nomogram to predict overall survival after radical nephrectomy].
    Xiong LB; Zou XP; Ning K; Luo X; Peng YL; Zhou ZH; Wang J; Li Z; Yu CP; Dong P; Guo SJ; Han H; Zhou FJ; Zhang ZL
    Zhonghua Zhong Liu Za Zhi; 2023 Aug; 45(8):681-689. PubMed ID: 37580273
    [No Abstract]   [Full Text] [Related]  

  • 5. B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma.
    Thompson RH; Webster WS; Cheville JC; Lohse CM; Dong H; Leibovich BC; Kuntz SM; Sengupta S; Kwon ED; Blute ML
    Urology; 2005 Nov; 66(5 Suppl):10-4. PubMed ID: 16194701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients.
    Parker WP; Cheville JC; Frank I; Zaid HB; Lohse CM; Boorjian SA; Leibovich BC; Thompson RH
    Eur Urol; 2017 Apr; 71(4):665-673. PubMed ID: 27287995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma.
    Fujii Y; Saito K; Iimura Y; Sakai Y; Koga F; Kawakami S; Kumagai J; Kihara K
    J Urol; 2008 Oct; 180(4):1290-5; discussion 1295-6. PubMed ID: 18707704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma.
    Thompson RH; Gillett MD; Cheville JC; Lohse CM; Dong H; Webster WS; Chen L; Zincke H; Blute ML; Leibovich BC; Kwon ED
    Cancer; 2005 Nov; 104(10):2084-91. PubMed ID: 16208700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival.
    Boorjian SA; Sheinin Y; Crispen PL; Farmer SA; Lohse CM; Kuntz SM; Leibovich BC; Kwon ED; Frank I
    Clin Cancer Res; 2008 Aug; 14(15):4800-8. PubMed ID: 18676751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma.
    Ficarra V; Martignoni G; Lohse C; Novara G; Pea M; Cavalleri S; Artibani W
    J Urol; 2006 Apr; 175(4):1235-9. PubMed ID: 16515968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preoperative CT-based deep learning radiomics model in predicting the stage, size, grade and necrosis score and outcome in localized clear cell renal cell carcinoma: A multicenter study.
    Nie P; Liu S; Zhou R; Li X; Zhi K; Wang Y; Dai Z; Zhao L; Wang N; Zhao X; Li X; Cheng N; Wang Y; Chen C; Xu Y; Yang G
    Eur J Radiol; 2023 Sep; 166():111018. PubMed ID: 37562222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma.
    Bearrick EN; Packiam V; Bhindi B; Lohse CM; Cheville JC; Mason RJ; Tollefson M; Harrington S; Dong H; Parker AS; Boorjian SA; Thompson RH; Leibovich BC
    Urol Oncol; 2021 Feb; 39(2):135.e1-135.e8. PubMed ID: 33309297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The radiomics-based tumor heterogeneity adds incremental value to the existing prognostic models for predicting outcome in localized clear cell renal cell carcinoma: a multicenter study.
    Yang G; Nie P; Yan L; Zhang M; Wang Y; Zhao L; Li M; Xie F; Xie H; Li X; Xiang F; Wang N; Cheng N; Zhao X; Wang N; Wang Y; Chen C; Yun C; Cui J; Duan S; Zhang R; Hao D; Wang X; Wang Z; Niu H
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2949-2959. PubMed ID: 35344062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score.
    Frank I; Blute ML; Cheville JC; Lohse CM; Weaver AL; Zincke H
    J Urol; 2002 Dec; 168(6):2395-400. PubMed ID: 12441925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy.
    Thompson RH; Dong H; Kwon ED
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):709s-715s. PubMed ID: 17255298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of B7-H1 overexpression in kidney cancer.
    Thompson RH; Kwon ED
    Clin Genitourin Cancer; 2006 Dec; 5(3):206-11. PubMed ID: 17239274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative Inflammation-Associated Blood Cell Markers in Patients with Non-Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Study.
    Cheng Y; Kou W; Zhu Y
    Int J Gen Med; 2023; 16():3067-3080. PubMed ID: 37489129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
    Thompson RH; Kuntz SM; Leibovich BC; Dong H; Lohse CM; Webster WS; Sengupta S; Frank I; Parker AS; Zincke H; Blute ML; Sebo TJ; Cheville JC; Kwon ED
    Cancer Res; 2006 Apr; 66(7):3381-5. PubMed ID: 16585157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma.
    Ficarra V; Novara G; Galfano A; Brunelli M; Cavalleri S; Martignoni G; Artibani W
    BJU Int; 2009 Jan; 103(2):165-70. PubMed ID: 18782313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems.
    Lamb GW; Aitchison M; Ramsey S; Housley SL; McMillan DC
    Br J Cancer; 2012 Jan; 106(2):279-83. PubMed ID: 22166802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.